Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib combine with SHR6390
Sponsor: Sun Yat-sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.